📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Rubicon Research Receives ₹17.25 Crore Income Tax Demand for AY 2023-24
Rubicon Research Limited has received an assessment order from the Income Tax Department for the Assessment Year 2023-24. The order includes additions and disallowances totaling ₹20.68 crore, primarily related to Arm's Length Pricing adjustments on international transactions. This has resulted in a total tax demand of ₹17.25 crore. The company has also been issued a show-cause notice for penalty proceedings but intends to contest the demand through an appeal, asserting a strong legal position.
Key Highlights
Total tax demand of ₹17.25 crore raised by the Income Tax Department for AY 2023-24.
Additions of ₹20.68 crore made due to Arm's Length Pricing adjustments on international transactions.
Show-cause notice issued for initiation of penalty proceedings under Section 270A.
Company is in the process of filing an appeal and remains confident in its legal merits.
The order was received on April 21, 2026, from the Assessment Unit, Mumbai.
💼 Action for Investors
Investors should monitor the progress of the tax appeal as a negative outcome would result in a cash outflow of ₹17.25 crore plus potential penalties. While tax disputes are common for companies with international operations, the size of the demand warrants attention.
Loading analysis...
Rubicon Research Acquires 85% Stake in Arinna Lifesciences for INR 175.92 Crores
Rubicon Research has announced the acquisition of an 85% equity stake in Arinna Lifesciences, marking its entry into the Indian domestic CNS formulations market. The transaction values Arinna at an enterprise value of INR 200 Crores, with Rubicon paying approximately INR 175.92 Crores for the majority stake. Arinna is a specialist in Central Nervous System (CNS) therapies with over 60 brands and a network of 4,000+ prescribers. For the nine months ended December 2025, Arinna reported a provisional revenue of INR 56.7 Crores and an EBITDA of INR 9.5 Crores.
Key Highlights
Acquisition of 85% equity ownership in Arinna Lifesciences for a consideration of INR 175.92 Crores.
Arinna reported 9M FY26 provisional revenue of INR 56.7 Crores and EBITDA of INR 9.5 Crores.
The deal values Arinna at an Enterprise Value of INR 200 Crores on a cash and debt-free basis.
Strategic entry into the Indian CNS market with access to 60+ brands and 4,000+ prescribers.
Rubicon aims to leverage its R&D playbook which scaled its US revenues 32x between FY15 and FY25.
💼 Action for Investors
Investors should look favorably on this acquisition as it diversifies Rubicon's revenue stream into the high-growth Indian domestic market. Monitor the successful integration of Arinna's distribution network with Rubicon's specialty product pipeline.
Loading analysis...
Rubicon Research to Acquire 85% Stake in Arinna Lifesciences for INR 175.92 Crores
Rubicon Research Limited has entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences, an Ahmedabad-based branded pharmaceutical marketing firm. The acquisition is valued at an enterprise value of INR 200 Crores, with Rubicon paying approximately INR 175.92 Crores in cash. Arinna specializes in the CNS and neuro-psychiatric therapeutic segments and reported a turnover of INR 71.5 Crores for FY25. This strategic move is intended to provide Rubicon with a domestic sales and distribution network to launch its specialty products and drug-device combinations in India.
Key Highlights
Acquisition of 85% equity stake in Arinna Lifesciences for approximately INR 175.92 Crores.
Target company Arinna reported a turnover of INR 71.50 Crores in FY25, up from INR 60.06 Crores in FY23.
The transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt-free basis.
Strategic focus on the CNS (Central Nervous System) segment, leveraging Rubicon's IP and Arinna's distribution network.
The acquisition is expected to be completed within one month from the date of signing.
💼 Action for Investors
This acquisition is a positive development as it provides Rubicon with a ready-made domestic platform to commercialize its CNS pipeline. Investors should monitor the integration and how this domestic presence impacts the company's overall margin profile.
Loading analysis...
Rubicon Research Q3 FY26: PAT Surges 91% to ₹73 Cr; Revenue Up 52% on Strong US Demand
Rubicon Research reported a robust Q3 FY26 with revenue growing 52% YoY to ₹476 crores, driven by broad-based growth and market share gains in the US. Net profit (PAT) saw a significant jump of 91% to ₹73 crores, while EBITDA margins remained stable at 22.7% despite increased outsourcing costs to meet high demand. The company is on track to operationalize its Pithampur facility by mid-2026 to expand into high-potent oncology and hormones. With a healthy ROCE of 34% and a cash reserve of ₹334 crores, the company is well-positioned for future growth.
Key Highlights
Revenue from operations grew 52% YoY to ₹476 crores in Q3 FY26, with 98% of revenue coming from the US.
Profit After Tax (PAT) increased by 91% YoY to ₹73 crores with an EPS of ₹4.41 for the quarter.
R&D investment stood at ₹52 crores (11% of revenue), which historically yields a 3.3x multiple in incremental sales.
Pithampur facility commercialization is expected by Q1 CY2027 to handle excess demand currently being outsourced.
Return on Capital Employed (ROCE) improved to 34%, reflecting high capital efficiency despite higher inventory levels for new launches.
💼 Action for Investors
Investors should find confidence in the strong revenue ramp-up and stable EBITDA margins despite temporary gross margin pressure from outsourcing. The upcoming Pithampur facility and high ROCE suggest a sustainable long-term growth trajectory in the specialty pharma space.
Loading analysis...
Rubicon Research Approves Merger with KIA Health Tech and Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, into the parent company to achieve operational synergies. KIA Health Tech, which was established for a manufacturing facility in Aurangabad, reported a net worth of ₹815.80 Lakhs and zero revenue as of March 2025. The company also strengthened its board by appointing Dr. Pradnya Saravade, a former IPS officer and SEBI investigation head, as an Independent Director. Concurrently, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board.
Key Highlights
In-principle approval for merger with 100% subsidiary KIA Health Tech to drive operational synergies.
Rubicon Research reported total revenue of ₹1,09,352.40 Lakhs and net worth of ₹66,778.57 Lakhs for FY25.
Appointment of Dr. Pradnya Saravade as Independent Woman Director for a 3-year term starting February 2026.
Resignation of Non-Executive Director Mr. Anand Agarwal, nominee of General Atlantic Singapore RR Pte Ltd.
Appointment of M/s. BNP & Associates as Secretarial Auditor for a five-year term through FY 2029-30.
💼 Action for Investors
The merger of the wholly-owned subsidiary is a positive step toward corporate simplification and cost efficiency without equity dilution. Investors should also note the high-profile board appointment which enhances the company's governance and regulatory oversight profile.
Loading analysis...
Rubicon Research Approves Merger with KIA Health Tech and Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, which has a net worth of ₹815.80 Lakhs, to achieve operational synergies. The company also appointed Dr. Pradnya Saravade, a former IPS officer with experience at SEBI and the CBI, as an Independent Woman Director for three years. Concurrently, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board. Rubicon reported a total revenue of ₹1,09,352.40 Lakhs and a net worth of ₹66,778.57 Lakhs for the period ending March 31, 2025.
Key Highlights
In-principle approval for merger with KIA Health Tech (Net worth ₹815.80 Lakhs) to streamline operations.
Appointment of Dr. Pradnya Saravade as Independent Woman Director, bringing regulatory expertise from SEBI and CBI.
Resignation of General Atlantic nominee Mr. Anand Agarwal from the Board of Directors.
Rubicon's FY25 revenue stood at ₹1,09,352.40 Lakhs with a net worth of ₹66,778.57 Lakhs.
BNP & Associates appointed as Secretarial Auditor for a five-year term through FY 2029-30.
💼 Action for Investors
The merger and the addition of a director with strong regulatory background enhance corporate governance and operational focus. Investors should view these structural changes as positive for long-term stability.
Loading analysis...
Rubicon Research to Merge KIA Health Tech Subsidiary; Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, to streamline operations. KIA Health Tech has a net worth of ₹815.80 Lakhs, while Rubicon reported a total revenue of ₹1,09,352.40 Lakhs for FY25. The company also strengthened its board by appointing Dr. Pradnya Saravade, a former IPS officer with SEBI and CBI experience, as an Independent Woman Director. These changes follow the resignation of Mr. Anand Agarwal, a nominee director from General Atlantic.
Key Highlights
In-principle approval for merger with KIA Health Tech Private Limited (Net worth ₹815.80 Lakhs).
Rubicon Research reported total revenue of ₹1,09,352.40 Lakhs and net worth of ₹66,778.57 Lakhs as of March 2025.
Appointment of Dr. Pradnya Saravade as Independent Woman Director for a 3-year term starting Feb 3, 2026.
Resignation of Mr. Anand Agarwal, Nominee Director of General Atlantic, due to other commitments.
Appointment of M/s. BNP & Associates as Secretarial Auditors for a five-year term through FY 2029-30.
💼 Action for Investors
The merger is a positive step toward corporate simplification and operational synergy. The addition of a director with significant regulatory and investigative experience enhances the company's governance profile.
Loading analysis...
Rubicon Research Approves Merger with Subsidiary and Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, which has a net worth of ₹815.80 Lakhs. The company also announced the appointment of Dr. Pradnya Saravade, a former IPS officer with SEBI investigation experience, as an Independent Woman Director for a three-year term. This board reshuffle includes the resignation of General Atlantic nominee Mr. Anand Agarwal. Additionally, BNP & Associates has been appointed as the Secretarial Auditor for a five-year term starting FY 2025-26 to enhance compliance oversight.
Key Highlights
In-principle approval for merger with KIA Health Tech Private Limited (Net worth: ₹815.80 Lakhs).
Rubicon Research reported total revenue of ₹1,09,352.40 Lakhs for the period ending March 31, 2025.
Appointment of Dr. Pradnya Saravade as Independent Woman Director, bringing significant regulatory and investigation experience.
Resignation of Mr. Anand Agarwal, Non-Executive Director nominated by General Atlantic, effective February 3, 2026.
Appointment of M/s. BNP & Associates as Secretarial Auditor for a term spanning FY 2025-26 to FY 2029-30.
💼 Action for Investors
The merger is a positive step toward operational synergy and structural simplification, while the appointment of a former SEBI official to the board strengthens governance. Investors should view these changes as constructive for long-term stability.
Loading analysis...
Rubicon Research Approves Merger with KIA Health Tech and Board Changes
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, to streamline operations and achieve synergies. KIA Health Tech, which was established for a manufacturing facility, had a net worth of ₹815.80 Lakhs and zero revenue as of March 2025, while Rubicon reported a revenue of ₹1,09,352.40 Lakhs. The company also appointed Dr. Pradnya Saravade, a former IPS officer with SEBI investigation experience, as an Independent Woman Director for a three-year term. Concurrently, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board.
Key Highlights
In-principle approval granted for the merger of wholly-owned subsidiary KIA Health Tech Private Limited with Rubicon Research.
Rubicon Research reported FY25 revenue of ₹1,09,352.40 Lakhs and a net worth of ₹66,778.57 Lakhs.
Appointment of Dr. Pradnya Saravade, a former IPS officer and SEBI investigator, as Additional Independent Woman Director.
Resignation of Mr. Anand Agarwal, Non-Executive Director nominated by General Atlantic, effective February 3, 2026.
Appointment of M/s. BNP & Associates as Secretarial Auditor for a five-year term starting FY 2025-26.
💼 Action for Investors
Investors should view the subsidiary merger as a positive step toward operational efficiency and the appointment of a director with strong regulatory background as a boost to corporate governance. Monitor the progress of the merger and the integration of the Aurangabad facility.
Loading analysis...
Rubicon Research Board Approves Merger of KIA Health Tech and New Director Appointment
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, to drive operational synergies. As of March 31, 2025, Rubicon reported a total revenue of ₹1,09,352.40 Lakhs and a net worth of ₹66,778.57 Lakhs. The board also appointed Dr. Pradnya Saravade, a former IPS officer with experience at SEBI and CBI, as an Independent Woman Director. Additionally, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board.
Key Highlights
In-principle approval for merger with KIA Health Tech (Net worth ₹815.80 Lakhs) to streamline operations.
Rubicon Research FY25 revenue stood at ₹1,09,352.40 Lakhs with a net worth of ₹66,778.57 Lakhs.
Appointment of Dr. Pradnya Saravade as Independent Woman Director for a 3-year term effective Feb 3, 2026.
Resignation of General Atlantic nominee Anand Agarwal from the board effective close of business Feb 3, 2026.
Appointment of BNP & Associates as Secretarial Auditor for a five-year term through FY 2029-30.
💼 Action for Investors
The consolidation of the subsidiary should improve operational efficiency and simplify the corporate structure. Investors should view the addition of a director with a strong regulatory and governance background as a positive for corporate oversight.
Loading analysis...
Rubicon Research Q3 Net Profit Jumps 91% YoY to ₹728 Million; Revenue Up 52%
Rubicon Research reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue growing 51.7% YoY to ₹4,755.29 million. Net profit surged by 91.2% YoY to ₹727.97 million, driven by robust operational growth despite a significant increase in R&D spending, which nearly doubled to ₹535.94 million. For the nine-month period, the company has already surpassed its full-year FY25 profit, reaching ₹1,699.50 million. Investors should note a post-quarter GST inspection mentioned in the auditor's report, though it has not yet impacted the financial results.
Key Highlights
Consolidated Revenue from operations rose 51.7% YoY to ₹4,755.29 million in Q3 FY26.
Net Profit after tax saw a massive jump of 91.2% YoY, reaching ₹727.97 million.
Research and Development (R&D) expenditure increased significantly to ₹535.94 million from ₹269.30 million YoY.
Basic Earnings Per Share (EPS) improved to ₹4.46 in Q3 FY26 compared to ₹2.50 in the same quarter last year.
Nine-month FY26 net profit of ₹1,699.50 million has already exceeded the full-year FY25 profit of ₹1,343.61 million.
💼 Action for Investors
The company shows exceptional growth momentum and high R&D focus, making it a strong growth play in the pharma space. Investors should monitor the outcome of the GST inspection mentioned in the auditor's notes for any potential liabilities.
Loading analysis...
Rubicon Research Q3 FY26 PAT Surges 91% YoY to ₹728 Million; Revenue Up 52%
Rubicon Research reported a robust Q3 FY26 with revenue growing 51.7% YoY to ₹4,755 million, driven by strong performance in the US market where 98% of revenue is USD-denominated. Net profit (PAT) saw a significant jump of 91.2% YoY to ₹728 million, while Operating EBITDA margins remained stable at 22.7%. Although gross margins saw a slight dip to 66.5% due to increased reliance on outsourced manufacturing, the company expects the upcoming Pithampur facility to be margin-accretive. The company maintains high R&D productivity with a 93% commercialization rate for its 83 active approved products.
Key Highlights
Q3 FY26 Revenue grew 51.7% YoY to ₹4,755 million; 9M FY26 PAT up 73.2% to ₹1,700 million
USD revenue reached $53 million for the quarter, representing a 46% increase compared to Q3 FY25
Operating EBITDA margins held steady at 22.7% despite higher outsourcing costs impacting gross margins
Product concentration is improving, with the top 10 products now contributing 53% of revenue versus 59% in 9M FY25
Pithampur facility ramp-up expected in Q1 CY27 to reduce outsourcing reliance and improve gross margins
💼 Action for Investors
Investors should favor the strong top-line and bottom-line growth and the company's ability to maintain EBITDA margins despite supply chain shifts. Monitor the operationalization of the Pithampur facility in mid-CY26 as a key catalyst for further margin expansion.
Loading analysis...
Rubicon Research Expands to Saudi Arabia with New Subsidiary AdvaGen S A
Rubicon Research Limited has successfully incorporated a wholly owned subsidiary, AdvaGen S A Company, in the Kingdom of Saudi Arabia as of January 13, 2026. The new entity is established with an initial share capital of SAR 1,00,000, consisting of 100 equity shares at a face value of SAR 1,000 each. This move marks the company's strategic entry into the Saudi Arabian pharmaceutical market to deal in various pharma products. The investment is a 100% cash consideration, ensuring full control by Rubicon Research.
Key Highlights
Incorporation of AdvaGen S A Company in Saudi Arabia as a 100% wholly owned subsidiary
Initial subscription cost of SAR 1,00,000 for 100 equity shares
The subsidiary will focus on the pharmaceutical industry and product dealing
Strategic geographic expansion into the Middle Eastern healthcare market
No governmental or regulatory approvals were required for the incorporation
💼 Action for Investors
Investors should view this as a positive step toward geographic diversification and market expansion. Monitor the subsidiary's future performance and its ability to scale operations in the GCC region.
Loading analysis...
Rubicon Research Shareholders Approve Promote Agreement and ESOP Ratifications
Rubicon Research Limited has successfully passed six key resolutions via postal ballot, including the approval of a Promote Agreement and the ratification of ESOP schemes from 2019 and 2022. All resolutions received the requisite majority, although Resolution 1 (Promote Agreement) and Resolution 2 (Shareholder Rights) saw notable dissent from public institutions at 26.27% and 38.63% respectively. The ESOP ratifications, covering both the company and its subsidiaries, passed with over 95% support. These approvals are critical for the company's post-listing governance and long-term incentive structures.
Key Highlights
Shareholders approved the Promote Agreement dated July 30, 2024, with 88.81% of total votes in favour.
Ratification of Investor and Management Shareholders rights passed with a 93.37% overall majority.
ESOP 2019 and ESOP 2022 schemes for the company and its subsidiaries were ratified with approximately 95.18% support.
Public institutions showed significant dissent on Resolution 2, with 38.63% of their votes cast against the ratification of shareholder rights.
💼 Action for Investors
Investors should monitor the impact of the Promote Agreement on future earnings and observe if the high institutional dissent on shareholder rights leads to any governance adjustments.